A kidney transplant patient told ILNA news agency that the supply of Myfortic, a medication used to prevent organ rejection in transplant patients, has been decreasing in recent months and is now "completely unavailable." According to him, pharmacies have announced that their stock has run out, and patients must seek alternative medications.
Secretary of the Kidney Transplant Scientific Association: Halting Import of Medication for Transplant Patients Puts Them at Risk of Organ Rejection
A kidney transplant patient reported a critical shortage of Myfortic, a medication essential for preventing organ rejection. Pharmacies are out of stock, forcing patients to look for alternatives. This situation poses a significant risk to the health of transplant patients in Iran.
👥 Key Players
📰 What Happened
There is a critical shortage of Myfortic, a medication necessary for kidney transplant patients to prevent organ rejection. Patients are now unable to find this medication in pharmacies and are being forced to seek alternatives.
- Myfortic is essential for preventing organ rejection in kidney transplant patients.
- Pharmacies across Iran have reported a complete stockout of this medication.
💡 Why It Matters
📚 Background
Iran has faced significant challenges in its healthcare system, particularly in accessing medications due to economic sanctions and domestic production limitations. Kidney transplants require strict medication regimens to prevent organ rejection.
🏷️ Entities Mentioned
Translated from the original and edited for English readers. View original source →
Translation confidence: 85%